COVID-19 Excess Deaths in Peru’s 25 States in 2020: Nationwide Trends, Confounding Factors, and Correlations With the Extent of Ivermectin Treatment by State
Juan J Chamie, Jennifer A Hibberd, David E Scheim
Cureus, doi:10.7759/cureus.43168
Introduction In 2020, nations hastened to contain an emerging COVID-19 pandemic by deploying diverse public health approaches, but conclusive appraisals of the efficacy of these approaches are elusive in most cases. One of the medicines deployed, ivermectin (IVM), a macrocyclic lactone having biochemical activity against SARS-CoV-2 through competitive binding to its spike protein, has yielded mixed results in randomized clinical trials (RCTs) for COVID-19 treatments. In Peru, an opportunity to track the efficacy of IVM with a close consideration of confounding factors was provided through data for excess deaths as correlated with IVM use in 2020, under semi-autonomous policies in its 25 states.
Methods To evaluate possible IVM treatment effects, excess deaths as determined from Peruvian national health data were analyzed by state for ages ≥60 in Peru's 25 states. These data were compared with monthly summary data for excess deaths in Peru for the period 2020-2021 as published by the WHO in 2022. To identify potential confounding factors, Google mobility data, population densities, SARS-CoV-2 genetic variations, and seropositivity rates were also examined.
Results Reductions in excess deaths over a period of 30 days after peak deaths averaged 74% in the 10 states with the most intensive IVM use. As determined across all 25 states, these reductions in excess deaths correlated closely with the extent of IVM use (p<0.002). During four months of IVM use in 2020, before a new president of Peru restricted its use, there was a 14-fold reduction in nationwide excess deaths and then a 13-fold increase in the two months following the restriction of IVM use. Notably, these trends in nationwide excess deaths align with WHO summary data for the same period in Peru.
Conclusions The natural experiment that was put into motion with the authorization of IVM use for COVID-19 in Peru in May 2020, as analyzed using data on excess deaths by locality and by state from Peruvian national health sources, resulted in strong evidence for the drug's effectiveness. Several potential confounding factors, including effects of a social isolation mandate imposed in May 2020, variations in the genetic makeup of the SARS-CoV-2 virus, and differences in seropositivity rates and population densities across the 25 states, were considered but did not appear to have significantly influenced these outcomes.
Additional Information Disclosures Human subjects: All authors have confirmed that this study did not involve human participants or tissue.
References
Aminpour, Cannariato, Safaeeardebili, In silico analysis of the multi-targeted mode of action of ivermectin and related compounds, Computation,
doi:10.3390/computation10040051Babalola, Ndanusa, Adesuyi, Ogedengbe, Thairu et al., A randomized controlled trial of ivermectin monotherapy versus HCQ, IVM, and AZ combination therapy in Covid-19 patients in Nigeria, J Infect Dis Epidemiol,
doi:10.23937/2474-3658/1510233Badr, Du, Marshall, Dong, Squire et al., Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study, Lancet Infect Dis,
doi:10.1016/S1473-3099(20)30553-3Bermúdez, If a doctor evaluates a person and prescribes ivermectin, they can use it
Boretti, Zinc augments the antiviral potential of HCQ/CQ and ivermectin to reduce the risks of more serious outcomes from COVID-19 infection, J Trace Elem Med Biol,
doi:10.1016/j.jtemb.2022.126954Bramante, Huling, Tignanelli, Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2201662Breakwater, IDL Reporters
Buonfrate, Chesini, Martini, High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2021.106516Cabezas, Fiestas, García-Mendoza, Palomino, Mamani et al., Dengue in Peru: a quarter of a century after its reemergence, Revista Peruana de Medicina Experimental y Salud Publica
Campbell, History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents, Curr Pharm Biotechnol,
doi:10.2174/138920112800399095Chaccour, Lines, Whitty, Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control, J Infect Dis,
doi:10.1086/653208Chahla, Ruiz, Ortega, Intensive treatment with ivermectin and iota-carrageenan as pre-exposure prophylaxis for COVID-19 in health care workers from Tucuman, Argentina, Am J Ther,
doi:10.1097/MJT.0000000000001433Chamie-Quintero, Hibberd, Scheim, Ivermectin for COVID-19 in Peru: 14-fold reduction in nationwide excess deaths, p<0.002 for effect by state, then 13-fold increase after ivermectin use restricted
Comercio, A trip to the black market of COVID-19
Crump, Ōmura, Ivermectin, wonder drug' from Japan: the human use perspective, Proc Jpn Acad Ser B Phys Biol Sci,
doi:10.2183/pjab.87.13De Castro, Jr, Gregianin, Burger, Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection, Leuk Lymphoma,
doi:10.1080/10428194.2020.1786559Desort-Henin, Kostova, Babiker, Caramel, Malamut, The SAIVE Trial, post-exposure use of ivermectin in COVID-19 prevention: efficacy and safety results
Guzzo, Furtek, Porras, Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects, J Clin Pharmacol,
doi:10.1177/009127002401382731Hazan, Gunaratne, Dolai, Clancy, Mccullough et al., Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients, Future Microbiol,
doi:10.2217/fmb-2022-0014Hibberd, Scheim, Google community mobility trends, seropositivity rates, comparisons of SINADEF data with who summary data, and other data items as useful in analysis of excess deaths during the COVID-19 pandemic in Peru
Hibberd, Scheim, Sharp reductions in COVID-19 case fatalities and excess deaths in Peru in close time conjunction, state-bystate
Juarez, Schcolnik-Cabrera, Dueñas-Gonzalez, The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug, Am J Cancer Res
Juscamayta-López, Carhuaricra, Tarazona, Valdivia, Rojas et al., Phylogenomics reveals multiple introductions and early spread of SARS-CoV-2 into Peru, J Med Virol,
doi:10.1002/jmv.27167Kerr, Baldi, Lobo, Regular use of ivermectin as prophylaxis for COVID-19 led up to a 92% reduction in COVID-19 mortality rate in a dose-response manner: results of a prospective observational study of a strictly controlled population of 88,
doi:10.7759/cureus.28624Kory, Meduri, Varon, Iglesias, Marik, Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19, Am J Ther,
doi:10.1097/MJT.0000000000001377Krolewiecki, Lifschitz, Moragas, Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial, EClinicalMedicine,
doi:10.1016/j.eclinm.2021.100959Lehrer, Rheinstein, Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2,
doi:10.21873/invivo.12134Lim, Hor, Tay, Efficacy of ivermectin treatment on disease progression among adults with mild to moderate covid-19 and comorbidities: the I-TECH randomized clinical trial, JAMA Intern Med,
doi:10.1001/jamainternmed.2022.0189Lima, None
López-Medina, 38 switched ivermectin (IVM) and placebo doses, failure of blinding, ubiquitous IVM use OTC in Cali, and nearly identical AEs for the IVM and control groups
López-Medina, López, Hurtado, Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial, JAMA,
doi:10.1001/jama.2021.3071Naggie, Boulware, Lindsell, Effect of higher-dose ivermectin for 6 days vs placebo on time to sustained recovery in outpatients with COVID-19: a randomized clinical trial, JAMA,
doi:10.1001/jama.2023.1650Naggie, Boulware, Lindsell, Effect of ivermectin vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial, JAMA,
doi:10.1001/jama.2022.18590Navarro, Camprubí, Requena-Méndez, Safety of high-dose ivermectin: a systematic review and meta-analysis, J Antimicrob Chemother,
doi:10.1093/jac/dkz524Nicolelis, Raimundo, Peixoto, Andreazzi, The impact of super-spreader cities, highways, and intensive care availability in the early stages of the COVID-19 epidemic in Brazil, Sci Rep,
doi:10.1038/s41598-021-92263-3Nih Covid-, Fluvoxamine: selected clinical data, limitations and interpretation
Oh, Lee, Khuong, Mobility restrictions were associated with reductions in COVID-19 incidence early in the pandemic: evidence from a real-time evaluation in 34 countries, Sci Rep,
doi:10.1038/s41598-021-92766-zPadilla-Rojas, Vega-Chozo, Galarza-Perez, Genomic analysis reveals local transmission of SARS-CoV-2 in early pandemic phase in Peru, bioRxiv,
doi:10.1101/2020.09.05.284604Puno, Starting tomorrow they will implement the Tayta operation led by the Peruvian Army
Reis, Silva, Silva, Effect of early treatment with ivermectin among patients with COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2115869Santin, Scheim, Mccullough, Yagisawa, Borody, Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19, New Microbes New Infect,
doi:10.1016/j.nmni.2021.100924Scheim, A deadly embrace: hemagglutination mediated by SARS-COV-2 spike protein at its 22 nglycosylation sites, red blood cell surface sialoglycoproteins, and antibody, Int J Mol Sci,
doi:10.3390/ijms23052558Scheim, Aldous, Osimani, Fordham, Hoy, When characteristics of clinical trials require perprotocol as well as intention-to-treat outcomes to draw reliable conclusions: three examples, J Clin Med. 2023,
doi:10.3390/jcm12113625Seet, Quek, Ooi, Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial, Int J Infect Dis,
doi:10.1016/j.ijid.2021.04.035Sempé, Lloyd-Sherlock, Martínez, Ebrahim, Mckee et al., Estimation of all-cause excess mortality by age-specific mortality patterns for countries with incomplete vital statistics: a populationbased study of the case of Peru during the first wave of the COVID-19 pandemic, Lancet Reg Health Am,
doi:10.1016/j.lana.2021.100039Shafiee, Athar, Gargari, Jafarabady, Siahvoshi et al., Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients, Virol J,
doi:10.1186/s12985-022-01829-8Shouman, Hegazy, Nafae, Use of ivermectin as a prophylactic option in asymptomatic family close contacts with patients of COVID-19 (NCT number: 04422561), J Clin Diagnostic Res
Stokes, Turner, Anselmi, Morciano, Hone, The relative effects of non-pharmaceutical interventions on wave one Covid-19 mortality: natural experiment in 130 countries,
doi:10.1186/s12889-022-13546-6Stone, Ndarukwa, Scheim, Changes in SpO2 on room air for 34 severe COVID-19 patients after ivermectin-based combination treatment: 62% normalization within 24 hours, Biologics,
doi:10.3390/biologics2030015Vallejos, Zoni, Bangher, Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial, BMC Infect Dis,
doi:10.1186/s12879-021-06348-5Wessa, net Free Statistics Software, Office for Research Development and Education, version 1.2.1
Yagisawa, Foster, Hanaki, Omura, Global trends in clinical studies of ivermectin in COVID-19, Jpn J Antibiot
